AbbVie’s patent on immunology therapy rejected
New Delhi: In good news for patients, Indian Patent Office has refused a patent on MNC firm AbbVie’s blockbuster immunology therapy Rinvoq, paving the way for affordable versions to enter the domestic market. In a recent hearing, the Delhi Patent Office held that the claimed invention was “obvious” and lacked inventive step, a violation of…